自体干细胞移植后持续来那度胺维持治疗可改善新诊断的多发性骨髓瘤患者的无进展生存率和总体生存率，自 2021 年 3 月以来一直是英国的护理标准。然而，关于其对患者日常生活影响的信息很少- 日常生活。本次服务评估旨在对在伦敦癌症中心接受来那度胺治疗的患者进行定性评估，以便该服务更好地符合患者的需求和期望。我们对持续接受来那度胺维持治疗的骨髓瘤患者进行了 20 名半结构化访谈在伦敦的一家专业癌症中心。临床团队成员确定了可能符合参与条件的参与者，并通过便利抽样选择了 10 名男性和 10 名女性患者，中位年龄为 58 岁（范围为 45-71 岁）。中位治疗持续时间为 11 个月（范围：1-60 个月）。参与者按照相同的半结构化访谈指南进行定性访谈，该指南旨在探索患者体验和对来那度胺的见解。数据分析采用反思性主题分析。四个总体主题如下：（i）来那度胺：了解其作用和基本原理； (ii) 将失去的无治疗期重新定义为恢复正常生活； (iii) 服用来那度胺的现实：平衡希望与障碍； (iv) 感激和委屈：探索对关怀和沟通的复杂看法。结果将用于通过定制沟通来加强临床服务，以更好地满足患者在做出治疗决定时的偏好。这项研究强调，大多数患者对持续服用来那度胺感到感激，并认为它减轻了对复发的一些恐惧。它揭示了不同年龄组副作用的差异；年轻患者报告没有/可以忽略不计的副作用，而几位患有合并症的老年患者则描述了明显的症状负担，有时会导致治疗停止，从而因感知到长时间缓解的丧失而感到痛苦。未来的研究应优先了解年轻多发性骨髓瘤患者的独特需求。© 2024。作者。

Continuous lenalidomide maintenance treatment after autologous stem cell transplantation delivers improvement in progression free and overall survival among newly diagnosed multiple myeloma patients and has been the standard of care in the UK since March 2021. However, there is scant information about its impact on patients' day-to-day lives. This service evaluation aimed to qualitatively assess patients receiving lenalidomide treatment at a cancer centre in London, in order that the service might better align with needs and expectations of patients.We conducted 20 semi-structured interviews among myeloma patients who were on continuous lenalidomide maintenance treatment at a specialist cancer centre in London. Members of the clinical team identified potentially eligible participants to take part, and convenience sampling was used to select 10 male and 10 female patients, median age of 58 (range, 45-71). The median treatment duration was 11 months (range, 1-60 months). Participants were qualitatively interviewed following the same semi-structured interview guide, which was designed to explore patient experience and insights of lenalidomide. Reflexive thematic analysis was used for data analysis.Four overarching themes were as follows: (i) lenalidomide: understanding its role and rationale; (ii) reframing the loss of a treatment-free period to a return to normal life; (iii) the reality of being on lenalidomide: balancing hopes with hurdles; (iv) gratitude and grievances: exploring mixed perceptions of care and communication. Results will be used to enhance clinical services by tailoring communication to better meet patients' preferences when making treatment decisions.This study highlights that most patients feel gratitude for being offered continuous lenalidomide and perceive it as alleviating some fears concerning relapse. It reveals variations in side effects in different age groups; younger patients reported no/negligible side effects, whilst several older patients with comorbidities described significant symptom burden, occasionally leading to treatment discontinuation which caused distress at the perceived loss of prolonged remission. Future research should prioritise understanding the unique needs of younger patients living with multiple myeloma.© 2024. The Author(s).